The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
As of 1 July 2024, you may notice a temporary increase in the numbers of X profiles with Unknown location. Click here to learn more.
| Title |
Pharmacologic management of bone-related complications and bone metastases in postmenopausal women with hormone receptor-positive breast cancer
|
|---|---|
| Published in |
Breast cancer targets and therapy, May 2016
|
| DOI | 10.2147/bctt.s97963 |
| Pubmed ID | |
| Authors |
Matthew Grzywacz, Denise Yardley |
| Abstract |
There is a high risk for bone loss and skeletal-related events, including bone metastases, in postmenopausal women with hormone receptor-positive breast cancer. Both the disease itself and its therapeutic treatments can negatively impact bone, resulting in decreases in bone mineral density and increases in bone loss. These negative effects on the bone can significantly impact morbidity and mortality. Effective management and minimization of bone-related complications in postmenopausal women with hormone receptor-positive breast cancer remain essential. This review discusses the current understanding of molecular and biological mechanisms involved in bone turnover and metastases, increased risk for bone-related complications from breast cancer and breast cancer therapy, and current and emerging treatment strategies for managing bone metastases and bone turnover in postmenopausal women with hormone receptor-positive breast cancer. |
X Demographics
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 1 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 1 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 28 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 28 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Bachelor | 6 | 21% |
| Student > Master | 5 | 18% |
| Researcher | 3 | 11% |
| Student > Postgraduate | 3 | 11% |
| Professor | 2 | 7% |
| Other | 7 | 25% |
| Unknown | 2 | 7% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 18 | 64% |
| Agricultural and Biological Sciences | 3 | 11% |
| Pharmacology, Toxicology and Pharmaceutical Science | 1 | 4% |
| Unspecified | 1 | 4% |
| Nursing and Health Professions | 1 | 4% |
| Other | 0 | 0% |
| Unknown | 4 | 14% |
Attention Score in Context
This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 25 May 2016.
All research outputs
#22,778,604
of 25,394,764 outputs
Outputs from Breast cancer targets and therapy
#285
of 324 outputs
Outputs of similar age
#269,370
of 311,961 outputs
Outputs of similar age from Breast cancer targets and therapy
#6
of 7 outputs
Altmetric has tracked 25,394,764 research outputs across all sources so far. This one is in the 1st percentile – i.e., 1% of other outputs scored the same or lower than it.
So far Altmetric has tracked 324 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 6.0. This one is in the 1st percentile – i.e., 1% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 311,961 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 1st percentile – i.e., 1% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 7 others from the same source and published within six weeks on either side of this one.